FDA places partial clinical hold on Bright Minds Biosciences Inc. drug application
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
The U.S. Food and Drug Administration issued a partial clinical hold on Bright Minds Biosciences Inc.'s investigational new drug application for Developmental and Epileptic Encephalopathies. The hold covers the planned Phase 2 study of BMB-101 in the United States, but does not affect the company's other ongoing clinical trials. The FDA cited identified toxicity in mice and inadequate pharmacokinetic and juvenile toxicity data as the primary reasons for the hold.
From manilatimes.net
Why it matters
A clinical hold halts the progression of drug development, directly impacting the potential revenue stream and valuation of the company involved. The decision affects the market perception of the drug's safety and efficacy profile.
From manilatimes.net
Who's involved
- FDARegulatory agency that issued the clinical hold on the drug application
- NasdaqStock exchange where Bright Minds Biosciences Inc. is listed
- Royal Bank of CanadaFinancial institution that may hold investments in the affected company
- MarketBeatPersonal finance blog that may revise its coverage of the company
- BenchmarkVenture capital firm that may revise its investment rating
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NasdaqSpeculative
The clinical hold could cause an immediate negative market price change on the stock exchange
- Royal Bank of CanadaSpeculative
The negative event might reduce the valuation of Royal Bank of Canada's existing investment position
Keep exploring
The entities involved
Related events
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.